Scaling Multi-Omics Analysis with Seqera to Accelerate Cancer Therapy Development
Read the full case study24x
faster turnaround time
81%
reduction in compute costs for RNA-Seq
55%
reduction in compute costs for WES
Aim
Streamline cancer therapy development and precision oncology to enable biomarker discovery, drug response profiling, and faster, more rigorous clinical insights.Challenges
- →Supporting diverse assays required constant pipeline updates and validation, straining limited resources and impacting reproducibility.
- →Handling complex sample types like PDX and organoids introduced variability and required custom QC, filtering, and species deconvolution.
- →Limited automation and legacy infrastructure slowed turnaround times, increased costs, and constrained scalability in a high-throughput setting.
- →Managing data across multiple systems posed challenges in unifying metadata and maintaining a coherent data provenance strategy.
— Gervaise Henry, VP of Data Engineering
Solution
Nextflow
Enable modular, containerized pipelines with full reproducibility and scalability, laying the foundation for automation and efficient cloud execution.
Seqera
Unified platform to automate end-to-end processing, manage cloud compute and storage, reduce costs, and deliver reproducible, high-quality data faster.
Fusion
Minimize I/O overhead and eliminate unnecessary data movement, for breakthrough pipeline performance and cost-efficiency.
Results
With Seqera, Champions Oncology were able to transform their workflow infrastructure by modernizing legacy pipelines, optimizing compute environments, and automating large-scale data analysis. As a result, they reduced RNA-seq compute costs by 81% and WES costs by 55%, while cutting turnaround time from days to hours. Additionally, centralized run tracking improved reproducibility and traceability, and greater automation freed the team to focus on higher-impact work. The result was a scalable, efficient, and future-ready data platform with sustainable strategies for pipeline updates and long-term data maintenance.
81%
Opportunity
Accelerate cancer therapy development
Fast, high quality, multi-omic data to support biomarker discovery, drug profiling, and clinical translation.
Advance precision oncology
Scalable models across 30+ cancer types (including rare indications), enabling mechanism-of-action studies and drug response modeling.
Drive operational efficiency
Scalable pipelines, automation, and modern infrastructure, delivering faster insights and reducing time-to-decision for internal and external teams.
About
Champions Oncology is a leading global oncology research organization dedicated to advancing precision cancer medicine. By leveraging its proprietary TumorGraft® technology platform, Champions provides cutting-edge preclinical and translational oncology services that accelerate drug development and improve clinical outcomes. The company collaborates closely with biopharmaceutical companies, academic institutions, and healthcare providers to develop innovative, patient-centric solutions.
Champions Oncology’s portfolio includes comprehensive patientderived xenograft (PDX) models, advanced bioinformatics, and multi-omics profiling to support target discovery, biomarker identification, and therapeutic optimization. With a commitment to scientific rigor, personalized medicine, and translational insight, Champions continues to play a vital
Learn more: www.championsoncology.com